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Background: Glucagon-like peptide-1 (GLP-1) is beneficial in relieving pain-related 
symptoms of Irritable bowel syndrome (IBS), a prevalent, multifactorial functional 
bowel disorder characterized by diarrhea and/or constipation, abdominal bloating and 
pain. Activation of myenteric neurons have been implicated in the inhibitory effects of 
GLP-1 on gastrointestinal motility, however the mechanisms of action underlying this 
are not clear.  
Methods: A rat model of IBS was used to examine physiological changes evoked by 
intraperitoneal administration of a GLP-1 receptor agonist, exendin-4. Behavioral and 
physiological analysis of stress-sensitive Wister Kyoto (WKY) rats was used to 
determine if administration of exendin-4, in the presence, or absence of neutralizing 
interleukin-6 receptor monoclonal antibodies, modified IBS-like symptoms. 
Immunofluorescence, calcium imaging and Western blotting techniques were used to 
investigate the potential role of enteric neural plexi and tight-junction protein 
expression in this effect.  
Key results: Consistent with the expression of GLP-1 and interleukin-6 receptors in 
both submucosal and myenteric ganglia, exendin-4 and interleukin-6 stimulated 
calcium responses in these neurons. In vivo administration of exendin-4 normalized 
stress-induced defecation and visceral pain sensitivity in WKY rats. No additional 
changes were noted in rats co-treated with exendin-4 and anti-interleukin-6 receptor 
antibodies. Mucosal expression of occludin, a tight junction protein was decreased by 
exendin-4. Centrally-regulated anxiety-like behaviors were not modified.  
Conclusions & inferences: These data suggest that intraperitoneal injection of 
exendin-4 improves bowel dysfunction in WKY rats without impacting on centrally-
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regulated anxiety-like behaviors. Modulation of enteric neuronal function and tight 
junction expression appear to underlie the functional benefits of this intervention.  
 
Keywords: Exendin-4, glucagon-like peptide-1, Wister Kyoto, colorectal distension, 
open-field, interleukin-6, stress. 
 
 
Key points   
 Glucagon-like peptide-1 (GLP-1) is beneficial in alleviating symptoms in patients 
with Irritable Bowel Syndrome (IBS), but the mechanisms underlying this effect 
remain unclear. 
 In Wister Kyoto (WKY) rats, which mimic symptoms of IBS, intraperitoneal 
injection of a GLP-1 receptor agonist, alleviated stress-induced defecation and 
visceral pain sensitivity, but did not impact on centrally-regulated anxiety-like 
behaviors.  
 Activation of peripheral GLP-1 receptors are likely to underlie the amelioration of 
IBS-like symptoms by GLP-1.  
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The prevalent functional bowel disorder, Irritable Bowel Syndrome (IBS), is 
characterized by chronic episodic bouts of abdominal pain, bloating and altered bowel 
habit, which may manifest as constipation, diarrhea or both 1. Although our 
understanding of the underlying pathophysiology has improved in recent times 2, a lack 
of sensitive and specific biomarkers continues to hamper diagnosis and treatment. 
Factors such as food, bile acids, antibiotics and infections, gender and adverse 
psychosocial events, particularly in early childhood, are all implicated in alterations in 
the gut epithelial barrier 3. This may result in increased intestinal leakiness causing 
immune activation and neuroendocrine responses. Combined with microbial changes 
this results in abnormal gut secretory and sensorimotor function 4-6.  
 
Post-prandial exacerbation of symptoms is problematic in many IBS patients 7-9, thus 
satiety-related hormones may have a role in IBS pathophysiology 10. Glucagon-like 
peptide-1 (GLP-1), which is released from intestinal L-cells in response to the arrival of 
nutrients in the intestinal lumen 11, is a circulating satiety hormone with a peak 
concentration that coincides with IBS post-prandial symptom manifestation 12. In 
addition to being an incretin hormone, GLP-1 also modifies gut function, inhibiting small 
intestinal secretion 13, gastrointestinal (GI) motility, gastric emptying and the migrating 
motor complex in both healthy controls and in patients with IBS 14-16. Furthermore, 
administration of a GLP-1 mimetic resulted in relief from gut spasms and pain in IBS 
patients 17,18. In a rat model of IBS, colonic mRNA and protein expression of GLP-1Rs 
was suppressed in diarrhea predominant-IBS and elevated in constipation-predominant 




Prior inflammatory gastroenteritis confers an increased susceptibility to develop IBS 20 
and IBS mucosal biopsies exhibit increased numbers of T-cells, intra-epithelial 
lymphocytes and mast cells 21. We have previously demonstrated that colonic secretions 
from the stress-sensitive Wistar Kyoto (WKY) rat model of IBS stimulates naïve 
submucosal neurons to a greater extent than secretions from low anxiety Sprague 
Dawley (SD) controls; an effect mediated in part by the pro-inflammatory cytokine, 
interleukin (IL)-6 22. Circulating levels of inflammatory cytokines such as IL-6 have 
reproducibly been found to be raised in IBS patients 23-25, particularly in diarrhea-
predominant IBS 26. However, more than just being a biomarker of IBS, IL-6 has 
functional effects in the GI tract, activating submucosal secretomotor neurons 27,28 and 
modulating mucosal ion transport and epithelial permeability 29,30. Moreover, 
neutralization of peripheral IL-6R signaling ameliorated visceral hypersensitivity and 
stress-induced defecation in the WKY rat model of IBS 31. As cross-talk between 
immune, endocrine and neural systems is likely to underlie the multifactorial nature of 
IBS 32, this study investigated if exendin-4 (Ex-4), a GLP-1 receptor (GLP-R) agonist, 
improves bowel dysfunction in WKY rats and determined if co-treatment with 




Materials and Methods 
Ethical approval 
All experiments were in full accordance with the European Community Council 
Directive (86/609/EEC) and the local University College Cork animal ethical committee. 
Rats were sacrificed by CO2 overdose and decapitation (#2011/015).  
 
Animals and tissue collection.  
To avoid interference from the female hormonal cycle in the assessment of the GI 
hormone, GLP-1, in bowel dysfunction, male Sprague Dawley (SD) control and stress-
sensitive Wister Kyoto (WKY) rats (8-12 weeks old, 200-250g), purchased from Envigo, 
Derbyshire, UK, were used. Animals were group-housed 5 per cage and maintained on a 
12/12 hour light-dark cycle (08.00-20.00) with a room temperature of 22±1oC. Food 
and water were available ad libitum. WKY rats are a stress-sensitive strain, which 
exhibit a high anxiety phenotype, visceral hypersensitivity and increased stress-related 
defecation 33-35. This model of brain-gut axis dysfunction has been validated as a rodent 
model of IBS 35,36. Rats were handled by the same researcher for at least five days prior 
to behavioral assessment.  
 
In the intervention study, all animal groups (SD: saline, WKY: saline, WKY: Ex-4 and 
WKY: Ex-4 & xIL-6R; n=12 per group) received an intraperitoneal (IP) injection of anti 
IgG (Jackson Immunoresearch, Westgrove PA, USA, 1mg/kg,) on day 0 to induce 
antibody tolerance. For the in vivo open field and colorectal distension (CRD) studies, 
WKY rats were randomly assigned to one of three groups (saline, Ex-4 or Ex- & xIL-6R). 
SD and WKY rats treated with an IP injection of saline on days 0, 3 and 10 were 
compared to verify the WKY phenotype of IBS-like bowel dysfunction. The saline-
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treated WKY rats were subsequently used as a control for Ex-4 and Ex-4 & xIL-6R 
treated WKY groups. The GLP-1R agonist, Ex-4 (1.25µg kg-1, Abcam, Cambridge, UK) 
was administered via IP injection 1 hour prior to the open field trial on day 7 and CRD 
on day 14 in both groups. In the Ex-4 & xIL-6R group, IP injections of xIL-6R (1mg kg-1, 
BioRad, Kidlington, OX5 1GE, UK) were delivered on day 0, 3, 6 and 10, as this has 
previously been shown to be effective in alleviating bowel dysfunction 31. Weights were 
monitored at day 0, 3, 6 and 10 during the trial. Whilst a species difference was noted 
between SD and WKY rats, no difference in weight gain between WKY groups was 
observed.  
 
Following CRD, rats were euthanized and trunk blood samples were collected in EDTA 
vacutainer tubes. Samples were centrifuged at 4000 rpm to separate the blood 
components. Plasma samples were stored at -80oC for later analysis. The distal colon 
(<4cms from the anus) was excised. For Western blot analysis, mucosal tissue was snap 
frozen in liquid nitrogen and stored at -80oC.  
 
Open Field Trial  
As previously described 35,37, animals were exposed to the psychological stress of being 
placed in the center of a brightly illuminated (~800 lux), white open field arena, (0.9m 
in diameter, 38cm in height) for a ten minute trial. Trials were conducted daily between 
09.00 and 13.00 and the arena was cleaned with 70% ethanol between trials. The 
number of fecal pellets excreted during the 10-minute exposure was recorded as an 
indication of stress-induced defecation. Trials were video-recorded and the distance 
and velocity of movement was analyzed offline using EthoVision software (Tracksys Ltd, 
Nottingham, England). The percentage water content of the fecal pellets excreted during 
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the open field trial was calculated by comparing the wet weight to the dry weigh (dried 
at 37oC for 24 hours). 
 
Colorectal Distension (CRD) 
Rats were fasted for 24 hours before CRD and acclimatized to the testing room for 30 
minutes prior to being lightly anaesthetized (inhaled 4% Isoflurane, Abbott Animal 
research, Ireland).  As previously described 37, a latex balloon (6 cm in length, Durex, NJ, 
USA) was inserted into the colon, 1 cm from the anus. The animals were permitted a 
recovery time of 10 min before the CRD procedure was initiated. A ramp distension 
protocol was used where the balloon was distended from 0 to 80mmHg over an 8-
minute time period (increasing by 10mmHg each minute) using a customized pressure 
control device (AstraZeneca R&D, Cambridge, UK). Pain behaviors in conscious rats in 
response to CRD are identified as contractions of the abdominal and hind limb 
musculature (abdominal withdrawal reflex), stretching or abdominal retractions 38. The 
threshold (mmHg) at which the first visibly identifiable pain behavior and the 
cumulative number of pain behaviors over the course of the trial was recorded. Offline 
analysis of recorded behaviors was carried out by a single researcher blinded to the rat 
strain and intervention.  
 
Western Blotting 
As previously described 39, the homogenates of colonic mucosal samples from SD and 
WKY rats one hour after CRD were denatured and separated on 12% sodium dodecyl 
sulfate polyacrylamide gels. Proteins were electro-transferred to PVDF membranes 
(ThermoFisher, Massachusetts, US), which were blocked and incubated with primary 
antibodies against occludin (Abcam, Cambridge, UK, 1:1,000), claudin-2 (Santa Cruz 
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Biotechnology, Tx, USA, 1:1,000) and CaV3.2 (Merck Millipore, Temaculla, CA, USA, 
1:200, overnight at 4oC). The membranes were subsequently incubated with 
complimentary horseradish peroxidase-conjugated secondary antibodies (Jackson 
ImmunoResearch, Westgrove, PA, USA, 1:5,000) before being visualized with an 
enhanced chemiluminescence detection system (Pierce ECL Western Blotting Substrate, 
ThermoFisher). Membranes were re-probed with antibodies against β-actin (Cell 
Signaling Technology, 1:1,000, overnight at 4oC), which acted as a reference protein. 
Images were captured using a GelDoc Image Reader (Las3000; Fujifilm, Tokyo, Japan) 
and analyzed using Multigauge v2.2 software (Fujifilm, Tokyo, Japan) to calculate 
protein densitometry. Protein bands are comparable only between each sub-group, 
which was conducted at the same time, under identical conditions. Protein samples 
(n=5) for each experimental group (SD saline, WKY saline, WKY Ex-4, WKY Ex-4 & xIL-
6R) were run in a single tank and probed under identical conditions.  
 
Mesoscale Discovery Biomarker Assay 
A sandwich immunoassay (V-PLEX Proinflammatory Panel 1 MesoScaleDiagnostics, 
Gaithersburg, MD, USA) was carried out according to the manufacturer’s guidelines to 
determine concentrations of IFNγ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13 and 
TNFα levels in plasma samples from a subset of treated WKY rats. The test was carried 
out in duplicate and protein levels were measured using electrochemiluminescence. 
Plates were read using MesoScale Discovery plate-reader (MESO QuickPlex SQ 120). A 
standard curve was generated from known cytokine concentrations and sample 
cytokine concentrations were extrapolated from the curve. 
 
Immunofluorescence & Confocal microscopy 
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In a separate study in SD rat distal colon, whole-mount preparations of longitudinal 
muscle myenteric plexus (LMMP) and submucosal plexus (SMP) tissue were prepared 
from (n=3 different tissue preparations per experiment). Cross sections of the whole 
colon were cryoprotected in 30% sucrose prior to cryosectioning (10µm in thickness, 
Leica Biosystems, Wetzler, Germany) and mounted on glass slides (VWR, Dublin 15, 
Ireland). All tissue was fixed in 4% paraformaldehyde (4oC, overnight), permeabilized 
with 0.1% Triton X-100 and blocked with 1% donkey serum (all from Sigma Aldrich, 
UK). The tissues were incubated with primary antibodies (at 4oC overnight) against 
glucagon-like peptide-1 (GLP-1, 1:250), GLP-1 receptor (GLP-1R, 1:250), interleukin-6 
(IL-6, 1:100) or IL-6 receptors (IL-6Rs, 1:250, all from Santa Cruz Biotechnology, Dallas, 
TX, US) and appropriate FITC- or TRITC- conjugated secondary antibodies (1:250, 2 
hours at room temperature, Jackson Immunoresearch, Westgrove, PA, US). Images were 
captured using a FVl0i-Olympus-confocal microscope with Fluoview software (FV10i-
SW). No non-specific fluorescence was detected in control experiments where tissues 
were incubated with primary antibodies or secondary antibodies alone or where anti 
GLP-1R and anti-IL-6R antibodies were neutralized with GLP-1 in excess prior to the 
staining protocol.  
 
Calcium imaging 
For calcium imaging studies, a LMMP or SMP tissue preparation from SD distal colon 
(n=3-4 rats per experiment) was pinned out in Sylgard (Sylgard 184 silicone elastomer 
kit, WPI, Sarasota FL, USA)-lined petri dishes superfused with carbogen-bubbled Krebs 
saline solution with 1μM nifedipine to inhibit smooth muscle contractions. The tissue 
was loaded with Fura-2 AM (7μM, 1 hr, Thermo Fisher Scientific, Waltham, MA, USA) in 
the dark and washed out prior to recording. Cytosolic changes in intracellular calcium 
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([Ca2+]i) were recorded from neuronal cell bodies using Cell R software (Olympus Soft 
imaging solutions, 1986-2009) to record excitation changes in intracellular calcium. 
Images were acquired at 2Hz using a Xenon/Mercury arc burner (Olympus, Melville, NY, 
US), a charge-coupled device digital camera (F-view II, Soft imaging system, Munster, 
Germany) and a 40x water-immersion objective on a fixed stage upright microscope 
(Olympus BX51WI, South-End-on-Sea, UK). Ganglionic neurons were identified based on 
morphology and responsivity to brief exposure to 75mM KCl, which was added at the 
end of each experiment. Responding neurons were defined as those with increases in 
intracellular calcium [Ca2+]i greater than two standard deviations from baseline 
(calculated as the average ratio during the 150 seconds preceding stimulus application). 
A perfusion system continuously superfused the colonic tissue with carbogen-bubbled 




Statistical analysis was carried out using GraphPad prism for Windows (version 5). The 
data are represented as box and whisker plots showing the median, with 5 and 95% 
percentile error bars. Student’s t-tests and one-way ANOVAs with Tukey’s multiple 
comparison post-hoc tests were used where appropriate. Statistical outliers (more than 
two standard deviations from the mean) were excluded. P≤0.05 was considered 





GLP-1 and IL-6 receptor expression in enteric neurons. 
Modulation of intestinal function by the GLP-1 receptor agonist, Ex-4, with or without 
xIL-6R, is likely to act peripherally, by binding to receptors expressed in gut tissue. 
Immunofluorescent studies were carried out on colonic tissue from SD rats, which 
exhibit normal GI function, to ascertain the pattern of expression of GLP-1, IL-6 and 
their receptors and to assess the potential for crosstalk between the hormone and 
cytokine. In colonic cross-sections (n=20 sections from 4 rats), epithelial GLP-1-labelled 
L-cells (green staining, indicated by arrows, figure 1A) were evident. GLP-1 receptor 
(GLP-1R, red staining) expression was more widespread in the mucosal layer and 
muscularis and co-localized with GLP-1 in enteric neurons (indicated by arrow, figure 
1A) and in a subset of L-cells (n=6 out of 19 L-cells,). Expression of IL-6 (green staining) 
was strongest in the neuronal plexi (indicated by arrow, figure 1B, n=20 sections from 4 
rats) of SD cross-sections. IL-6R expression (red staining) was evident in the muscular 
layers, epithelial cells and particularly in enteric neurons.  
 
Dual-labelling of myenteric neurons, which regulate GI contractile activity and colonic 
transit, was carried out to assess the ganglionic expression of GLP-1, IL-6 and their 
receptors. Distinct subsets of myenteric neurons expressed GLP-1 (red staining) or IL-6 
(green staining), although 25% (19/75 neurons in 12 ganglia) of IL-6 positive neurons 
also expressed GLP-1 (indicated by arrows, figure1C, n=4 LMMP tissue preparations). A 
different pattern of expression was noted in myenteric ganglia for IL-6 receptors and 
GLP-1 receptors. IL-6R immunofluorescence (green staining) was strongly localized to 
neuronal cell bodies. Although GLP-1R immunofluorescence was also present on 
neuronal cell bodies, it was much more strongly expressed in intra-ganglionic cells 
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surrounding the neurons (figure 1D, n=4 LMMP tissue preparations). Sensitivity of 
these neurons to the receptor agonists was confirmed using calcium imaging, where a 
rise in intracellular Ca2+ was interpreted as an indicator of neuronal excitability. 
Application of the GLP-1R agonist, exendin-4 (Ex-4, 10µM, 3 min) stimulated a robust 
increase in intracellular calcium ([Ca2+]i) in myenteric neurons (figure 1E). IL-6 (1nM, 3 
min) similarly stimulated myenteric neurons although the amplitude of the response 
was lower as compared to Ex-4 (repeated measures ANOVA, F(2,27)=2.7, p<0.001). 
Interestingly, when both IL-6 and Ex-4 were applied together the amplitude of the 
calcium response was significantly smaller than when the GLP-1 mimetic, Ex-4 was 
applied alone (p<0.001, figure 1E). 
 
Submucosal neurons regulate GI absorption and secretion. Similar to myenteric 
neurons, submucosal ganglia were immunopositive for GLP-1 and IL-6 protein (n=4 
SMP preparations from SD rat colons). A subset (30%, n=26 out of 87 neurons in 12 
submucosal ganglia) of IL-6-(green staining) expressing neurons were co-stained with 
GLP-1 (red staining, indicated by arrow, figure 1F) but many neurons expressed either 
GLP-1 or IL-6. IL-6R immunofluorescence (green staining) was primarily localized to 
submucosal neuron cell bodies, whereas GLP-1R expression (red staining) was more 
strongly expressed in cells surrounding these neurons (n=4 SMP tissue preparations, 
figure 1G). Submucosal neurons were sensitive to Ex-4 (10µM, 3 min), responding with 
an increase in [Ca2+]i. IL-6 (1nM, 3 min) evoked a calcium response in the same neurons, 
although this was smaller in amplitude than the Ex-4-evoked response (repeated 
measures ANOVA, F(2,53)=64.7, p<0.001). However, when both were applied together 




A GLP-1 mimetic normalizes stress-induced defecation in WKY rats. 
IBS-like traits exhibited by stress-sensitive WKY rats include augmented colonic transit, 
expressed as increased defecation rates, in response to an environmental stressor 35. 
Our cohort of saline-treated WKY rats (n=12) displayed increased stress-induced 
defecation in the open field arena as compared to saline-treated SD rats (n=11, 
p<0.0001, Student’s t-test, figure 2). To investigate the potential of GLP-1R agonists to 
inhibit bowel motility 14, WKY rats were treated with Ex-4 (1.25µg/kg I.P., 1 hour prior 
to the open field trial), in the absence or presence of xIL-6R (1mg/kg, four I.P. injections 
over two weeks) and assessed in the open field arena. When compared to saline-treated 
WKY rats (n=10), Ex-4 treatment reduced the number of fecal boli excreted in the 
anxiogenic environment of the open field arena (n=12, p<0.0001, one-way ANOVA with 
Tukey post-test). However, no additive effect was noted in WKY rats co-treated with 
xIL-6R (n=11, figure 2).  
 
Ex-4 treated WKY rats exhibited modified mucosal expression of tight junction 
proteins. 
To determine whether stimulation of submucosal neurons by Ex-4 resulted in 
modulation of GI absorpto-secretory function, we examined the water content of the 
fecal pellets excreted in the open field arena. No significant difference was detected 
between saline-treated SD (n=5) and saline-treated WKY rats (n=9, Student’s t-test, 
p=0.123). Moreover, in vivo treatment with Ex-4 in the absence (n=6) or presence of 
xIL-6R (n=4), had no impact on water content in WKY fecal pellets (p=0.253, one-way 




As tight junction proteins are also important in intestinal barrier permeability, protein 
expression of claudin-2 and occludin from homogenized colonic mucosal tissue was 
compared between experimental groups. Increased expression of claudin-2 is thought 
to increase barrier permeability 40, but, as compared to SD rats (n=5) expression of this 
protein was reduced in WKY colons (n=5, p=0.043, Student’s t-test). No change in 
expression of claudin-2 was evident in WKY colonic mucosa from rats administered Ex-
4 (n=5) or Ex-4 with xIL-6R (n=5 rats, p=0.137, one-way ANOVA with Tukey post-test, 
figure 3B). Depletion of the tight junction protein, occludin is linked with increased 
intestinal barrier permeability 41, however, no change in mucosal expression of occludin 
was noted between SD (n=4) and WKY rats (n=5, p=0.15, Student’s t-test,). Nonetheless, 
WKY rats treated with Ex-4 (n=4), but not Ex-4 and xIL-6R (n=5), had lower expression 
of occludin (p=0.011, figure 3C).  
 
Visceral hypersensitivity in WKY rats is not evident following Ex-4 treatment. 
Consistent with previous reports of visceral hypersensitivity to CRD (Gibney et al., 
2010; Gunter et al., 2000; O'Mahony et al., 2010), we observed that the threshold at 
which CRD (0-80mmHg over 8 minutes) evoked pain behaviors was lower in WKY rats 
(n=10) than SD rats (n=9, p=0.02, Student’s t-test, figure 4A). There was no significant 
difference in the pain threshold to CRD between saline-treated (n=10), Ex-4-treated 
(n=11) or Ex-4 plus xIL-6R-treated (n=10) WKY rats (p=0.439, one-way ANOVA with 
Tukey post-test, figure 4A). However, in WKY rats treated with Ex-4 in the presence or 
absence of xIL-6R, the threshold to the first pain behavior were not different to the SD 
control rats (p=0.556, one-way ANOVA with Tukey post-test). Consistent with the link 
between expression of Cav3.2, T-type calcium channels and visceral pain sensitivity 42, 
we found that mucosal expression of Cav3.2 was increased in saline-treated WKY rats 
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(n=4) as compared to SD controls (n=5, p=0.05, Student’s t-test, figure 4B).  However, 
mucosal expression Cav3.2 was not different in WKY rats treated with Ex-4 (n=4) or co-
treatment with Ex-4 plus xIL-6R (n=5) as compared to saline-treated WKY rats 
(p=0.151, one-way ANOVA with Tukey post-test).  
 
Intraperitoneal Ex-4 does not modify anxiety-like behaviors in WKY rats. 
The sensitivity of WKY rats to stress was evident by the display of anxiety-like 
behaviors in the open field arena. WKY rats (n=11) were less inclined to explore the 
exposed inner zone of the open field arena compared to SD controls (n=11), spending 
less time in the inner zone (p=0.015, Student’s t-test, figure 5A) and making fewer 
entries into the exposed inner zone (p=0.0002, Student’s t-test, figure 5B). Time spent in 
the inner circle of the open field arena by WKY rats treated with Ex-4 (n=11) or Ex-4 
plus xIL-6R (n=11) remained significantly lower than control SD rats (p=0.0114, one-
way ANOVA with Tukey post-test, figure 5A). Similarly, the number of entries to the 
central region by treated WKY rats was significantly less than SD controls (p<0.0001, 
one-way ANOVA with Tukey post-test, figure 5B).  
 
Ex-4 increased circulating levels of anti-inflammatory IL-13 in WKY rats. 
Shortening of colon length can indicate inflammation  43 and saline-treated WKY rats 
(n=11) had shorter colons than SD comparators (n=11, p= 0.009, Student’s t-test, figure 
6). Colonic length in WKY rats treated with Ex-4 (n=10) or co-treated with Ex-4 plus 
xIL-6R (n=11) did not show any significant difference to saline-treated WKY rats 
(p=0.858, one-way ANOVA with Tukey post-test, figure 6) and tended towards being 




Circulating pro- and anti-inflammatory cytokines were compared between saline-
treated WKY rats and those treated with Ex-4 or Ex-4 plus xIL-6R (n= plasma from 4-6 
rats per group). TNFα, a pro-inflammatory cytokine and IL-4, an anti-inflammatory 
cytokine, were not detectable in any of the plasma samples. No significant changes in 
circulating levels of pro-inflammatory IFNγ, IL-1β, IL-6 or IL-8 were detected (p>0.05, 
one-way ANOVA with Tukey post-test, table 1). The anti-inflammatory cytokines, IL-2 
(p=0.227, one-way ANOVA with Tukey post-test), IL-10 (p=0.161, one-way ANOVA with 
Tukey post-test) and IL-12p70 (p=0.313, one-way ANOVA with Tukey post-test, table 1) 
were not modified by the treatments. However, Ex-4 induced an increase in circulating 
levels of the anti-inflammatory cytokine, IL-13 (p=0.022, one-way ANOVA with Tukey 








Ingestion of food has been linked to the genesis of IBS symptoms such as abdominal 
bloating and diarrhea 7-9. The onset or deterioration of symptoms can become apparent 
in up to 60% of IBS patients within 15 – 180 minutes of food intake 44 . Possible 
mechanisms by which nutrients induce GI symptoms include activation of 
mechanoreceptors due to gut distension, activation of immune cells, nutrient sensing by 
enteroendocrine cells or a combination of these 45. Our study has used a pre-clinical rat 
model of IBS to investigate mechanisms underlying the reported beneficial effects of 
administering GLP-1R agonists to patients with functional bowel disorders 17. We also 
investigated whether co-treatment with neutralizing IL-6R antibodies, which we have 
previously shown to improve IBS-like symptoms in WKY rats  32, enhanced the 
therapeutic efficacy of administering a GLP-1 mimetic.  
 
GLP-1 can act as a classic hormone, a paracrine molecule or a neuromodulatory factor. 
The peak of circulating GLP-1 levels coincides with post-prandial symptom 
manifestation in IBS patients 12 and in addition to its role as an incretin hormone, GLP-1 
also modifies GI function 13, both in healthy controls 46 and in patients with IBS 14-16. 
Given our previous work 10, where we determined that fasting GLP-1 levels are 
decreased in diarrhea-predominant IBS patients, one could propose that supplementing 
patients with GLP-1 could be beneficial in improving GI symptoms 17.  In contrast, 
circulating levels of the pro-inflammatory cytokine, IL-6, which can modify neural 
regulation of gut function 31,36,47, is elevated in diarrhea-predominant IBS patients 26. In 
the WKY rat model, which exhibits IBS-like symptoms, inhibition of IL-6 signaling 
improved visceral pain sensitivity and stress-induced defecation, although these 
symptoms were not normalized 31. Given the multi-factorial nature of IBS 
19 
 
pathophysiology, post-prandial secretion of GLP-1 in conjunction with low-grade 
immune activation typified by elevated levels of IL-6, could contribute to symptom 
exacerbation. Thus, the therapeutic potential of a GLP-1 mimetic alone and in 
conjunction with neutralizing IL-6R antibodies was investigated in the WKY rat model 
of IBS.  
 
WKY rats exhibited anxious behaviors such as freezing and avoiding the exposed inner 
zone of the arena of the open field arena and, although the water content was not 
significantly increased, they defecated more often than their control comparators. 
Although the half-life of Ex-4 is longer than GLP-1, which is rapidly degraded by 
dipeptidyl peptidase-4, subcutaneously injected Ex-4 is reported to only have a half-life 
of ~70 minutes 48. Therefore, in our studies Ex-4 was administered one hour prior to 
behavioral assessments. Decreased excretion of fecal boli in Ex-4 treated WKY rats is 
consistent with reports in humans that Ex-4 mollified colonic transit 14-16,46. We have 
previously established the intricate relationship between hormones and immune 
molecules and demonstrated the efficacy of xIL-6R in reducing stress-induced 
defecation in WKY rats 31.  However, in this study, no further change in stress-induced 
defecation was observed in WKY rats co- treated with xIL-6R.  
Interestingly, whilst both GLP-1 and IL-6 protein and receptors were detected in 
healthy SD myenteric neurons, distinct patterns of expression were evident, with 
minimal co-localization of neurons expressing protein or receptors. This may indicate 
that different population of neurons, which may be stimulatory or inhibitory may be 
activated by the receptor agonists. IL-6Rs were localized to myenteric neuron cell 
bodies, whereas punctate GLP-1R expression was stronger in intra-ganglionic cells 
surrounding the neurons. Glial cells surround ganglionic neurons and are known to 
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actively modulate neuronal excitability, however, GLP-1R expression was not detected 
in S100-labelled myenteric glial cells 49. The immunofluorescently-visualized GLP-1 
receptors may therefore be predominantly expressed on innervating fibers. Indeed, 
GLP-1Rs have been detected in human colonic nerve fibers and dorsal root ganglion 
cells 50. Interestingly, the number of GLP-1R-positive fibers is increased in patients with 
inflammatory bowel disease 50, which, similar to IBS, is characterized by elevated levels 
of pro-inflammatory cytokines such as IL-6 51. It is interesting, given that GLP-1 and IL-6 
receptors are not commonly expressed in the same cells, that cross-talk is apparent in 
the neurostimulatory actions of the receptor agonists 31,49. The amplitude of the calcium 
response evoked by Ex-4 is suppressed when IL-6 is co-applied. Although this 
relationship needs to be researched further, neuronal cross-talk between these 
molecules could impact of colonic function. In submucosal neurons which regulate 
intestinal absorption and secretion, protein expression of IL-6 and GLP-1 was also 
commonly detected in separate groups of neurons. IL-6R expression was typically found 
in neuronal cell bodies, whereas GLP-1R expression was strongest in the intraganglionic 
cells surrounding the neurons, which could include glial cells or innervating fibers. 
Similar to previous reports in acute preparations of submucosal neurons, application of 
both Ex-4 10 and IL-6 22 evoked calcium responses. However, in contrast to the effects in 
myenteric neurons, when Ex-4 was applied in conjunction with IL-6, the amplitude of 
the calcium response was larger than the control responses, indicating the relationship 
between these molecules differs between neuronal plexi, which could further impact on 
colonic function.  
 
Epithelial expression of tight junction proteins which regulate barrier permeability, was 
altered in WKY rats as compared to SD controls. Increased expression of claudin-2 is 
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thought to increase barrier leakiness 40, whereas we noted decreased expression in 
saline-treated WKY rats . Moreover, there is a trend towards increased expression of 
occludin in WKY rats, when depletion of this tight junction protein is linked with 
increased intestinal barrier permeability 41. This suggests that the colonic epithelial 
barrier in WKY rats is less permeable that the SD control which is consistent with 
evidence that demonstrated that baseline colonic ion transport and cholinergic‐induced 
ion transport was decreased in WKY rats as compared to SD rats 52. Claudin-2 
expression was not modified in either treatment group but interestingly, colonic 
mucosa from WKY rats treated with Ex-4 alone, but not Ex-4 and xIL-6R had reduced 
expression of occludin, suggesting that Ex-4 could modify barrier permeability. 
Nonetheless, the GLP-1 mimetic had no significant effect on water content of fecal 
pellets excreted by WKY rats.  
 
Pain threshold to CRD in saline-treated WKY rats was not significantly different to WKY 
rats treated with Ex-4 alone, or with Ex-4 and xIL-6R. However, these two groups were 
not significantly different to SD controls, suggesting some improvement in these groups. 
Cav3.2 T-type calcium channels are linked to visceral pain sensitivity 42 and similar to 
previous studies 31, mucosal expression of these channels were elevated in WKY rats. 
However, expression of this channel was not modified by either treatment. Although 
GLP-1Rs are present in the CNS, and GLP-1 can cross the blood brain barrier 53, no 
changes in centrally-regulated anxiety-like behaviors in WKY rats were apparent 
following treatments. 
 
Consistent with the multi-factorial nature of IBS, interplay between endocrine and 
immune factors contribute to bowel dysfunction in WKY rats 31. Several studies have 
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reported altered cytokine profiles in IBS 24,25,54 and WKY rats 55, where stress hormones 
and immune cytokines were investigated in relation to the pathophysiology of 
depression. Ex-4 has anti-inflammatory effects in the intestine 56 and may suppress pro-
inflammatory cytokines in human obese and diabetic patients 57. Shortening of colon 
length can be indicative of inflammation 43. Indeed, we previously reported altered 
colon lengths in two models of bowel dysfunction 35. In this cohort of WKY rats, colonic 
length was shorter than SD rats, suggesting immune activation. However, this was not 
significantly altered by treatment with Ex-4 or Ex-4 plus xIL-6R. The in vivo treatments 
did not alter any of the pro-inflammatory cytokines in WKY rats however, circulating 
levels of the anti-inflammatory Th2 cytokine, IL-13 was elevated following Ex-4 
treatment. IL-13 has been reported to induce the replacement of epithelial cells with 
goblet cells, an observation that we have previously reported in the proximal colon of 
WKY rats 35 and elevated levels of this cytokine are consistent with the purported anti-
inflammatory actions of GLP-1 58.  
 
Conclusions. 
Administration of a GLP-1 mimetic, Ex-4, normalized stress-induced defecation in the 
WKY rat model of bowel dysfunction, with more modest effects on visceral pain 
sensitivity and immune activation and no changes in centrally-orchestrated anxiety-like 
behaviors. Modulation of enteric neuronal function and tight junction expression appear 
to underlie the functional benefits of this intervention. Although we have previously 
reported that gut dysfunction in this animal model can be improved by in vivo treatment 
with xIL-6R, no additive effect was noted when WKY rats were co-treated with Ex-4 and 
xIL-6R. These studies begin to elucidate the mechanisms underlying the beneficial 
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Table 1: Treatment-evoked changes in immune cytokines in WKY plasma. 
 
Pro-inflammatory cytokines in WKY plasma 
 Saline treated 
(pg ml-1) 
Ex-4 treated  
(pg ml-1) 
Ex-4 & xIL-6R 
treated (pg ml-1) 
P value (One-way 
ANOVA) 
IFN-γ 0.51 ±0.03 0.58 ±0.04 0.63 ±0.05 P=0.18 
IL-1β 0.87 ±0.06 0.86 ±0.09 0.64 ±0.11 P=0.18 
IL-6 0.01 ±0.01 0.016 ±0.007 0.022 ±0.009 P=0.15 
IL-8 0.27 ±0.075 0.21 ±0.03 0.19 ±0.01 P=0.34 
TNFα ND ND ND  
 
Anti-inflammatory cytokines in WKY plasma 
 Saline treated  
(pg ml-1) 
Ex-4 treated  
(pg ml-1) 
Ex-4 & xIL-6R 
treated (pg ml-1) 
P values (One-
way ANOVA) 
IL-2 0.18 ±0.006 0.16 ±0.01 0.15 ±0.004 P=0.22 
IL-4 ND ND ND  
IL-10 0.03 ±0.006 0.02 ±0.002 0.04 ±0.01 P=0.16 
IL-12p70 0.082 ±0.008 0.094 ±0.005 0.09 ±0.004 P=0.31 





Figure and Table Legends 
Figure 1: Expression of IL-6 and GLP-1 in the distal colon 
A: The representative immunofluorescent images in cross sections from the distal colon 
of Sprague Dawley (SD) rats illustrate expression of glucagon-like peptide-1 (GLP-1, 
green staining) in mucosal L-cells (indicated by arrows) and GLP-1 receptors (GLP-1R, 
red staining). B: Interleukin-6 (IL-6, green staining) and IL-6 receptor (IL-6R, red 
staining) immunofluorescence were highly expressed in enteric ganglia (indicated by 
arrows). Scale bars: 200µm. C: The representative immunofluorescent images show 
protein expression of IL-6 (green staining) and GLP-1 (red staining) in myenteric 
neurons. Some neurons expressed both proteins (indicated by arrows). D: Distinct IL-
6R (green staining) and GLP-1R (red staining) expression were evident in SD distal 
colonic myenteric ganglia. Scale bars: 20µm. E: The box and whisker plot and 
representative calcium trace illustrates the neurostimulatory actions of Ex-4 and IL-6 in 
myenteric neurons. F: The representative immunofluorescent images show protein 
expression of IL-6 (green staining) and GLP-1 (red staining) and G: IL-6R (green 
staining) and GLP-1R (red staining) in SD distal colonic submucosal ganglia. Scale bars: 
20µm. H: The box and whisker plot and representative calcium trace illustrates the 
neurostimulatory actions of exendin-4 (Ex-4) and IL-6 in SD submucosal neurons. *** 
indicates p<0.001.  
 
Figure 2: Ex-4 inhibits stress-induced defecation in the Wister Kyoto rat model of 
IBS. 
 
The box and whisker plots illustrate the number of fecal boli excreted in the open field 
arena by Sprague Dawley (SD) and Wister Kyoto (WKY) rats treated with saline, 
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exendin-4 (Ex-4) or Ex-4 & anti-interleukin-6 receptor monoclonal antibodies (xIL-6R). 
*** indicates p<0.001.  
 
Figure 3: Mucosal expression of tight junction proteins was modified by Ex-4 
treatment. 
A: The water content in fecal boli excreted in the open field arena by Sprague Dawley 
(SD) and Wister Kyoto (WKY) rats treated with saline, Ex-4 or Ex-4 & anti-interleukin-6 
receptor monoclonal antibodies (xIL-6R) was comparable. B: The box and whisker plots 
and the representative Western blots illustrate relative protein expression (calculated 
as a ratio of β-actin expression) of the tight junction proteins, Claudin-2 and C: occludin 
in each experimental group. * indicates p<0.05. 
 
 Figure 4: Visceral hypersensitivity in WKY rats is not evident following treatment 
with Ex-4. 
A: The box and whisker plots illustrate the pressure (mmHg-1) at which Sprague Dawley 
(SD) and Wister Kyoto (WKY) rats treated with saline, Exendin-4 (Ex-4) or Ex-4 & anti-
interleukin-6 receptor monoclonal antibodies (xIL-6R) exhibit their first pain behavior 
in response to colorectal distention. B: The plots and representative blots show mucosal 
expression of the T-type calcium channels, Cav3.2, in SD rats and WKY rats treated with 
Ex-4 alone or Ex-4 combined with xIL-6R. * indicates p<0.05. NS indicates non-
significant. 
 




A: The box and whisker plot illustrates anxiety-like behaviors in Wister Kyoto (WKY) 
rats as compared to Sprague Dawley (SD) controls. WKY rats spent less time in the 
anxiogenic inner circle of the open field arena and B: made fewer exploratory entries to 
the inner zone. This was not modified by treatment with exendin-4 (Ex-4) or co-
treatment with Ex-4 and anti-interleukin-6 receptor monoclonal antibodies (xIL-6R). * 
** and *** indicate p<0.05, p<0.01 and p<0.001, respectively. 
 
Figure 6: Shortened colon length in WKY rats is normalized by Ex-4 treatment. 
The box and whisker plot shows colon length is decreased in saline-treated Wister 
Kyoto (WKY) rats as compared to Sprague Dawley (SD) controls. WKY colons from rats 
treated with exendin-4 (Ex-4) and Ex-4 plus anti-interleukin-6 receptor monoclonal 
antibodies (xIL-6R) were not significantly different to saline-treated WKY controls. ** 
indicates p<0.01. 
 
Table 1  
The table illustrates circulating levels of pro- and anti-inflammatory cytokines in plasma 
samples taken from Wister Kyoto (WKY) rats administered saline, exendin-4 (Ex-4) or 
Ex-4 plus neutralizing anti-IL-6 receptor antibodies (xIL-6R) in vivo. ND: not detected.   
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